All In Biotech

NDA 021016 · Upjohn

Relpax

Eletriptan Hydrobromide · Oral

Novel

Last checked: Nov 19, 2026Latest source record: Mar 24, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2002

Dec 26, 2002

Approved uses

1

Original approval plus efficacy supplements

Registered trials

2

0 Phase 3, 1 recruiting

FAERS reports

7,038

3,693 serious, 97 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 15, 2024.

RELPAX is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use: • Use only if a clear diagnosis of migraine has been established. If a patient has no response to the first migraine attack treated with RELPAX, reconsider the diagnosis of migraine before RELPAX is administered to treat any subsequent attacks. • RELPAX is not intended for the prevention of migraine attacks. • Safety and effectiveness of RELPAX have not been established for cluster headache. RELPAX is a serotonin (5-HT 1B/1D ) receptor agonist (triptan) indicated for the acute treatment of migraine with or without aura in adults ( 1 ) Limitations of Use: • Use only after a clear diagnosis of migraine has been established ( 1 ) • Not indicated for the prophylactic therapy of migraine ( 1 ) • Not indicated for the treatment of cluster headache ( 1 )

Mechanism: Eletriptan binds with high affinity to 5-HT 1B , 5-HT 1D and 5-HT 1F receptors, has modest affinity for 5-HT 1A , 5-HT 1E , 5-HT 2B and 5-HT 7 receptors. Migraines are likely due to local cranial vasodilatation and/or to the release of sensory neuropeptides (vasoactive intestinal peptide, substance P and calcitonin gene-related peptide) through nerve endings in the trigeminal system. The therapeutic activity of RELPAX for the treatment of migraine headache is thought to be due to the agonist effects at the 5-HT 1B/1D receptors on intracranial blood vessels (including the arterio-venous...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • RELPAX · ELETRIPTAN HYDROBROMIDE EQ 20MG BASE · TABLET, ORAL · Prescription · TE AB
  • RELPAX · ELETRIPTAN HYDROBROMIDE EQ 40MG BASE · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Eletriptan Hydrobromide" as an intervention, any sponsor and status, largest first.

All 2 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective913
  • migraine863
  • headache733
  • nausea502
  • pain425
  • fatigue335
  • vomiting329
  • malaise292
  • dizziness270
  • off label use231
  • anxiety223
  • feeling abnormal214

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004208
2005183
2006112
2007131
2008134
200975
2010322
2011282
2012451
2013408
2014478
2015618
2016689
2017406
2018392
2019672
2020415
2021244
2022256
2023170
2024177
2025129
202686

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Relpax (Eletriptan Hydrobromide)

2024 spending

$2.8M

Beneficiaries

449

2,201 claims

Per beneficiary

$6,185

$77.50 per unit

View as table
YearSpending
2020$4,037,854
2021$3,485,987
2022$3,063,189
2023$3,092,247
2024$2,776,861

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 6 on PubMed

Sponsor: Upjohn

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.